X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nexium-Generic (esomeprazole magnesium) is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease and NSAID-associated gastric ulcer.
Lead Product(s): Esomeprazole Magnesium
Therapeutic Area: Gastroenterology Product Name: Nexium-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2024
Details:
Glenmark will register and commercialize BeiGene’s, Tevimbra (tislelizumab), in India. It is indicated for adult patients with unresectable or metastatic esophageal squamous cell carcinoma.
Lead Product(s): Tislelizumab
Therapeutic Area: Oncology Product Name: Tevimbra
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 21, 2024
Details:
Combigan-Generic (brimonidine tartrate/timolol maleate) is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated IOP.
Lead Product(s): Timolol Maleate
Therapeutic Area: Ophthalmology Product Name: Combigan-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2024
Details:
The company has received approval from the US Food and Drug Administration (USFDA) for generic version for Acetaminophen and Ibuprofen tablets (250 mg/125 mg) indicated for pain and inflammation.
Lead Product(s): Ibuprofen,Paracetamol
Therapeutic Area: Neurology Product Name: Advil-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
Under the partnership, Glenmark and Pfizer will co‐market abrocitinib, a Janus kinase 1 (JAK1) inhibitor, provides rapid itch relief and sustained disease control in India under the brand names Jabryus and Cibinqo, respectively.
Lead Product(s): Abrocitinib
Therapeutic Area: Dermatology Product Name: Cibinqo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 31, 2024
Details:
The collaboration aims to accelerate new drug discovery in cancer treatment combining Ichnos' research and development proficiencies in novel biologics with those of Glenmark in new small molecules, including GRC 54276, to treat hematological malignancies and solid tumors.
Lead Product(s): GRC 54276,Pembrolizumab
Therapeutic Area: Oncology Product Name: GRC 54276
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Ichnos Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 30, 2024
Details:
Glenmark will be responsible for further developing, registering, and commercializing KN035 (envafolimab), approved in China for the treatment of adult patients with previously treated MSI-H or dMMR advanced solid tumor, in multiple geographies around the World.
Lead Product(s): Envafolimab
Therapeutic Area: Oncology Product Name: KN035
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Jiangsu Alphamab
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 25, 2024
Details:
Lirafit (liraglutide biosimilar) is a glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs). It is now approved in India for the treatment of adult patients with type 2 diabetes mellitus.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Lirafit
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
Zita DM contains the DPP4 inhibitor, Teneligliptin, the SGLT2 inhibitor, Dapagliflozin, and Metformin SR in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes.
Lead Product(s): Teneligliptin Hydrobromide,Dapagliflozin,Metformin
Therapeutic Area: Endocrinology Product Name: Zita DM
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
Under the agreements, Glenmark will receive from Cassiopea, the exclusive right to commercialize Winlevi (clascoterone cream), used on the skin (topical) to treat acne vulgaris in people 12 years of age and older, in 15 EU countries as well as in South Africa and the UK.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Cassiopea
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Licensing Agreement September 27, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
